The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Combination of enmetazobactam, invented by scientists associated with Chennai-based pharma firm Orchid Pharma in 2008, and ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has published its report on new drug approvals in 2022, Advancing Health Through Innovation: New Drug Therapy ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
The CD19-targeted rare disease medicine Uplizna was one of the crown jewels in Amgen’s $27.8 billion buyout of Horizon ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Moderna's RSV shot is the first messenger RNA-based (mRNA) vaccine not for COVID-19 to be approved in the United States. It ...